- Voglibose IP 0.2
- Voglibose IP 0.3
- Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia with insulin resistance and inadequate insulin secretion.
- In diabetic patients, Postprandial Hyperglycaemia (PPHG) is a direct and independent risk factor for the development of Cardiovascular Diseases (CVD) or stroke caused by premature atherosclerosis.
- Alpha-glucosidase inhibitors (AGIs) inhibit the enzyme α-glucosidase at the brush border of the intestinal epithelium, thus blocking the absorption of carbohydrates in the small intestine. They are administered with the first bite of a carbohydrate-containing meal and limit postprandial hyperglycemia without causing hypoglycemia.
- Type-II Diabetes Mellitus
- Diabetic Dyslipidemia
- Drug class: Competitive α glucosidase inhibitors (α-GIs)
- Voglibose delays the absorption as well as digestion of dietary polysaccharides by reversibly inhibiting carbohydrate digestive enzymes like sucrose, maltose, isomaltase, etc. This results in a reduction in PPHG.
- Valigobose may also facilitate mobilisotary α endogenous glycogen-like peptide 1 (GLP-1), which has an inhibitory action on glycogen, thus lowering fasting glucose levels too.
- Voglibose treatment has resulted in an increased release of GLP-1, which is an insulinotropic hormone and it has also increased the release of GLP-1, which is known to enhance insulin secretion and insulin sensitivity.